Myeloid-derived suppressor cells coming of age.
Reads0
Chats0
TLDR
The origin and nature of myeloid-derived suppressor cells, as well as their distinctive features and biological roles in cancer, infectious diseases, autoimmunity, obesity and pregnancy are discussed.Abstract:
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells generated during a large array of pathologic conditions ranging from cancer to obesity. These cells represent a pathologic state of activation of monocytes and relatively immature neutrophils. MDSCs are characterized by a distinct set of genomic and biochemical features, and can, on the basis of recent findings, be distinguished by specific surface molecules. The salient feature of these cells is their ability to inhibit T cell function and thus contribute to the pathogenesis of various diseases. In this Review, we discuss the origin and nature of these cells; their distinctive features; and their biological roles in cancer, infectious diseases, autoimmunity, obesity and pregnancy.read more
Citations
More filters
Journal ArticleDOI
Inflammation and Cancer: Triggers, Mechanisms, and Consequences.
TL;DR: How tumor-promoting inflammation closely resembles inflammatory processes typically found during development, immunity, maintenance of tissue homeostasis, or tissue repair is discussed and the distinctions between tissue-protective and pro-tumorigenic inflammation are illuminated.
Journal Article
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-CELL suppressive activity
Kiavash Movahedi,Martin Guiliams,Jan Van den Bossche,Rafael Van den Bergh,Conny Gysemans,Alain Beschin,Patrick De Baetselier,Jo A. Van Ginderachter +7 more
TL;DR: This work identified 2 distinct MDSC subfractions with clear morphologic, molecular, and functional differences, and refined tumor-induced MDSCs functions by uncovering mechanistically distinct M DSC subpopulations, potentially relevant for MDSc-targeted therapies.
Journal ArticleDOI
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
Jonas Schulte-Schrepping,Nico Reusch,Daniela Paclik,Kevin Baßler,Stephan Schlickeiser,Bowen Zhang,Benjamin Krämer,Tobias Krammer,Sophia Brumhard,Lorenzo Bonaguro,Elena De Domenico,Daniel Wendisch,Martin Grasshoff,Theodore S. Kapellos,Michael Beckstette,Tal Pecht,Adem Saglam,Oliver Dietrich,Henrik E. Mei,Axel Schulz,Claudia Conrad,Désirée Kunkel,Ehsan Vafadarnejad,Cheng-Jian Xu,Cheng-Jian Xu,Arik Horne,Miriam Herbert,Anna Drews,Charlotte Thibeault,Moritz Pfeiffer,Stefan Hippenstiel,Andreas C. Hocke,Holger Müller-Redetzky,Katrin-Moira Heim,Felix Machleidt,Alexander Uhrig,Laure Bosquillon de Jarcy,Linda Jürgens,Miriam Stegemann,Christoph R. Glösenkamp,Hans-Dieter Volk,Christine Goffinet,Markus Landthaler,Emanuel Wyler,Philipp Georg,Maria Schneider,Chantip Dang-Heine,Nick Neuwinger,Kai Kappert,Rudolf Tauber,Victor M. Corman,Jan Raabe,Kim Melanie Kaiser,Michael To Vinh,Gereon Rieke,Christian Meisel,Thomas Ulas,Matthias Becker,Robert Geffers,Martin Witzenrath,Christian Drosten,Norbert Suttorp,Christof von Kalle,Florian Kurth,Florian Kurth,Florian Kurth,Kristian Händler,Joachim L. Schultze,Joachim L. Schultze,Anna C. Aschenbrenner,Anna C. Aschenbrenner,Yang Li,Yang Li,Jacob Nattermann,Birgit Sawitzki,Antoine-Emmanuel Saliba,Leif E. Sander,Angel Angelov,Robert Bals,Alexander Bartholomäus,Anke Becker,Daniela Bezdan,Ezio Bonifacio,Peer Bork,Thomas Clavel,Maria Colomé-Tatché,Andreas Diefenbach,Alexander T. Dilthey,Nicole Fischer,Konrad U. Förstner,Julia-Stefanie Frick,Julien Gagneur,Alexander Goesmann,Torsten Hain,Michael Hummel,Stefan Janssen,Jörn Kalinowski,René Kallies,Birte Kehr,Andreas Keller,Sarah Kim-Hellmuth,Christoph Klein,Oliver Kohlbacher,Jan O. Korbel,Ingo Kurth,Kerstin U. Ludwig,Oliwia Makarewicz,Manja Marz,Alice C. McHardy,Christian Mertes,Markus M. Nöthen,Peter Nürnberg,Uwe Ohler,Stephan Ossowski,Jörg Overmann,Silke Peter,Klaus Pfeffer,Anna R. Poetsch,Alfred Pühler,Nikolaus Rajewsky,Markus Ralser,Olaf Rieß,Stephan Ripke,Ulisses Nunes da Rocha,Philip Rosenstiel,Philipp H. Schiffer,Eva-Christina Schulte,Alexander Sczyrba,Oliver Stegle,Jens Stoye,Fabian J. Theis,Janne Vehreschild,Jörg Vogel,Max von Kleist,Andreas Walker,Jörn Walter,Dagmar Wieczorek,John Ziebuhr +137 more
TL;DR: This study provides detailed insights into the systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the myeloid cell compartment associated with severe COVID-19.
Journal ArticleDOI
Targeting macrophages: therapeutic approaches in cancer.
TL;DR: The state of the art of TAM-targeting strategies is evaluated, focusing on the limitations and potential side effects of the different therapies such as toxicity, rebound effects and compensatory mechanisms.
Journal ArticleDOI
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
TL;DR: The authors advocate the need to assess a combination of immune determinants and the importance of evaluating the functional status of specific cell populations to increase prognostic and/or predictive power.
References
More filters
Journal Article
The pilot study.
TL;DR: A randomized controlled experiment is designed to test whether access to affordable day care (in the form of subsidies, for example) would incentivize Saudi mothers to search actively for employment and to remain employed once they are hired.
Journal ArticleDOI
Myeloid-derived suppressor cells as regulators of the immune system.
TL;DR: The origin, mechanisms of expansion and suppressive functions of MDSCs, as well as the potential to target these cells for therapeutic benefit are discussed.
Journal ArticleDOI
Coordinated regulation of myeloid cells by tumours
TL;DR: This work considers myeloid cells as an intricately connected, complex, single system and focuses on how tumours manipulate the myeloids system to evade the host immune response.
Journal ArticleDOI
Tumor-associated macrophages: from mechanisms to therapy.
TL;DR: Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.